Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

NCT03377400 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Durvalumab

Sponsor

Samsung Medical Center